VectivBio

About:

VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.

Website: https://vectivbio.com

Twitter/X: vectivbio

Top Investors: Bpifrance, OrbiMed, Marshall Wace, Versant Ventures, Forbion Capital Partners

Description:

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Total Funding Amount:

$399M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2019-01-01

Contact Email:

info(AT)vectivbio.com

Founders:

Luca Santarelli

Number of Employees:

51-100

Last Funding Date:

2022-10-13

IPO Status:

Public

© 2025 bioDAO.ai